Download PDF
Semin Thromb Hemost 2015; 41(02): 195-207
DOI: 10.1055/s-0035-1546465
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Which Patients May Benefit from Dose Adjustment of Non-Vitamin K Antagonist Oral Anticoagulants?

Paul K. L. Chin
1   Department of Medicine, University of Otago, Christchurch, New Zealand
› Author Affiliations
Further Information

Publication History

Publication Date:
17 February 2015 (online)

    Permissions and Reprints

Abstract

The commercially available non-vitamin K antagonist oral anticoagulants (NOAC) are an emerging therapeutic class, which includes dabigatran, rivaroxaban, apixaban, and edoxaban. Dose adjustment of the NOAC currently takes into account the presence of particular patient characteristics that may alter NOAC concentrations. These characteristics include the presence of renal impairment and concomitant drugs affecting proteins involved with the transport and metabolism of the NOAC. NOAC concentrations reflect anticoagulant activity; some studies have shown some correlation with the risks of adverse events, while others have not, and the association is debated by workers in the field. However, dose adjustment based on characteristics before dosing assumes that the patient has drug oral availability and clearance at the mean of patients with these characteristics. Direct quantification of NOAC concentrations, for example, through the use of calibrated coagulation assays, is likely to add further to individualization of dosing to the particular patient.

Keywords

dabigatran - rivaroxaban - apixaban - edoxaban - dose adjustment - blood coagulation - monitoring - pharmacokinetics
 

  • References

  • 1 You JJ, Singer DE, Howard PA , et al; American College of Chest Physicians. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl): e531S-e575S
    CrossrefPubMedGoogle Scholar
  • 2 Falck-Ytter Y, Francis CW, Johanson NA , et al; American College of Chest Physicians. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl): e278S-e325S
    CrossrefPubMedGoogle Scholar
  • 3 Camm AJ, Lip GY, De Caterina R , et al; ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33 (21) 2719-2747
    CrossrefPubMedGoogle Scholar
  • 4 Culebras A, Messé SR, Chaturvedi S, Kase CS, Gronseth G. Summary of evidence-based guideline update: prevention of stroke in nonvalvular atrial fibrillation: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2014; 82 (8) 716-724
    CrossrefPubMedGoogle Scholar
  • 5 January CT, Wann LS, Alpert JS , et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014; 64 (21) 2246-2280
    CrossrefPubMedGoogle Scholar
  • 6 Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146 (12) 857-867
    CrossrefPubMedGoogle Scholar
  • 7 Desai NR, Krumme AA, Schneeweiss S , et al. Patterns of Initiation of Oral Anticoagulants in Patients with Atrial Fibrillation- Quality and Cost Implications. Am J Med 2014; 127 (11) 1075-1082.e1
    CrossrefPubMedGoogle Scholar
  • 8 Kirley K, Qato DM, Kornfield R, Stafford RS, Alexander GC. National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes 2012; 5 (5) 615-621
    CrossrefPubMedGoogle Scholar
  • 9 Connolly SJ, Ezekowitz MD, Yusuf S , et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361 (12) 1139-1151
    CrossrefPubMedGoogle Scholar
  • 10 Patel MR, Mahaffey KW, Garg J , et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365 (10) 883-891
    CrossrefPubMedGoogle Scholar
  • 11 Granger CB, Alexander JH, McMurray JJ , et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365 (11) 981-992
    CrossrefPubMedGoogle Scholar
  • 12 Giugliano RP, Ruff CT, Braunwald E , et al; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369 (22) 2093-2104
    CrossrefPubMedGoogle Scholar
  • 13 Schulman S, Kearon C, Kakkar AK , et al; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361 (24) 2342-2352
    CrossrefPubMedGoogle Scholar
  • 14 Schulman S, Kearon C, Kakkar AK , et al; RE-MEDY Trial Investigators; RE-SONATE Trial Investigators. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013; 368 (8) 709-718
    CrossrefPubMedGoogle Scholar
  • 15 Schulman S, Kakkar AK, Goldhaber SZ , et al; RE-COVER II Trial Investigators. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 2014; 129 (7) 764-772
    CrossrefPubMedGoogle Scholar
  • 16 Agnelli G, Buller HR, Cohen A , et al; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369 (9) 799-808
    CrossrefPubMedGoogle Scholar
  • 17 Agnelli G, Buller HR, Cohen A , et al; PLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368 (8) 699-708
    CrossrefPubMedGoogle Scholar
  • 18 Bauersachs R, Berkowitz SD, Brenner B , et al; EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363 (26) 2499-2510
    CrossrefPubMedGoogle Scholar
  • 19 Büller HR, Prins MH, Lensin AW , et al; EINSTEIN–PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366 (14) 1287-1297
    CrossrefPubMedGoogle Scholar
  • 20 Büller HR, Décousus H, Grosso MA , et al; Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369 (15) 1406-1415
    CrossrefPubMedGoogle Scholar
  • 21 Alexander JH, Lopes RD, James S , et al; APPRAISE-2 Investigators. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011; 365 (8) 699-708
    CrossrefPubMedGoogle Scholar
  • 22 Mega JL, Braunwald E, Wiviott SD , et al; ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366 (1) 9-19
    CrossrefPubMedGoogle Scholar
  • 23 Fuji T, Fujita S, Kawai Y , et al. Safety and efficacy of edoxaban in patients undergoing hip fracture surgery. Thromb Res 2014; 133 (6) 1016-1022
    CrossrefPubMedGoogle Scholar
  • 24 Hori M, Matsumoto M, Tanahashi N , et al; J-ROCKET AF study investigators. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation – the J-ROCKET AF study. Circ J 2012; 76 (9) 2104-2111
    CrossrefPubMedGoogle Scholar
  • 25 US Food and Drug Administration. PRADAXA Label Information. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022512s025.pdf . Accessed November 16, 2014
    PubMedGoogle Scholar
  • 26 US Food and Drug Administration. XARELTO Label Information. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022406s011lbl.pdf . Accessed November 16, 2014
    PubMedGoogle Scholar
  • 27 US Food and Drug Administration. ELIQUIS Label Information. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/202155s009lbl.pdf . Accessed November 16, 2014
    PubMedGoogle Scholar
  • 28 Eriksson BI, Dahl OE, Rosencher N , et al; RE-MODEL Study Group. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007; 5 (11) 2178-2185
    CrossrefPubMedGoogle Scholar
  • 29 Eriksson BI, Dahl OE, Rosencher N , et al; RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007; 370 (9591) 949-956
    CrossrefPubMedGoogle Scholar
  • 30 Ginsberg JS, Davidson BL, Comp PC , et al; RE-MOBILIZE Writing Committee. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009; 24 (1) 1-9
    CrossrefPubMedGoogle Scholar
  • 31 Eriksson BI, Dahl OE, Huo MH , et al; RE-NOVATE II Study Group. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial. Thromb Haemost 2011; 105 (4) 721-729
    Article in Thieme ConnectPubMedGoogle Scholar
  • 32 Eriksson BI, Borris LC, Friedman RJ , et al; RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358 (26) 2765-2775
    CrossrefPubMedGoogle Scholar
  • 33 Kakkar AK, Brenner B, Dahl OE , et al; RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008; 372 (9632) 31-39
    CrossrefPubMedGoogle Scholar
  • 34 Lassen MR, Ageno W, Borris LC , et al; RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358 (26) 2776-2786
    CrossrefPubMedGoogle Scholar
  • 35 Turpie AG, Lassen MR, Davidson BL , et al; RECORD4 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009; 373 (9676) 1673-1680
    CrossrefPubMedGoogle Scholar
  • 36 Cohen AT, Spiro TE, Büller HR , et al; MAGELLAN Investigators. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med 2013; 368 (6) 513-523
    CrossrefPubMedGoogle Scholar
  • 37 Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009; 361 (6) 594-604
    CrossrefPubMedGoogle Scholar
  • 38 Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P ; ADVANCE-2 investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010; 375 (9717) 807-815
    CrossrefPubMedGoogle Scholar
  • 39 Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM ; ADVANCE-3 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010; 363 (26) 2487-2498
    CrossrefPubMedGoogle Scholar
  • 40 Goldhaber SZ, Leizorovicz A, Kakkar AK , et al; ADOPT Trial Investigators. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med 2011; 365 (23) 2167-2177
    CrossrefPubMedGoogle Scholar
  • 41 Roehrig S, Straub A, Pohlmann J , et al. Discovery of the novel antithrombotic agent 5-chloro-N-((5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-ylmethyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. J Med Chem 2005; 48 (19) 5900-5908
    CrossrefPubMedGoogle Scholar
  • 42 Wong PC, Pinto DJ, Zhang D. Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor. J Thromb Thrombolysis 2011; 31 (4) 478-492
    CrossrefPubMedGoogle Scholar
  • 43 Furugohri T, Isobe K, Honda Y , et al. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost 2008; 6 (9) 1542-1549
    PubMedGoogle Scholar
  • 44 Hauel NH, Nar H, Priepke H, Ries U, Stassen JM, Wienen W. Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem 2002; 45 (9) 1757-1766
    CrossrefPubMedGoogle Scholar
  • 45 Douxfils J, Mullier F, Loosen C, Chatelain C, Chatelain B, Dogné JM. Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature. Thromb Res 2012; 130 (6) 956-966
    CrossrefPubMedGoogle Scholar
  • 46 Douxfils J, Mullier F, Robert S, Chatelain C, Chatelain B, Dogné JM. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 2012; 107 (5) 985-997
    Article in Thieme ConnectPubMedGoogle Scholar
  • 47 Douxfils J, Chatelain C, Chatelain B, Dogné JM, Mullier F. Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide. Thromb Haemost 2013; 110 (2) 283-294
    Article in Thieme ConnectPubMedGoogle Scholar
  • 48 Samama MM, Mendell J, Guinet C, Le Flem L, Kunitada S. In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux. Thromb Res 2012; 129 (4) e77-e82
    CrossrefPubMedGoogle Scholar
  • 49 Stangier J, Rathgen K, Stähle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007; 64 (3) 292-303
    CrossrefPubMedGoogle Scholar
  • 50 Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005; 61 (12) 873-880
    CrossrefPubMedGoogle Scholar
  • 51 Becker RC, Yang H, Barrett Y , et al. Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban—an oral, direct and selective factor Xa inhibitor. J Thromb Thrombolysis 2011; 32 (2) 183-187
    CrossrefPubMedGoogle Scholar
  • 52 Ogata K, Mendell-Harary J, Tachibana M , et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 2010; 50 (7) 743-753
    CrossrefPubMedGoogle Scholar
  • 53 Oake N, Jennings A, Forster AJ, Fergusson D, Doucette S, van Walraven C. Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis. CMAJ 2008; 179 (3) 235-244
    CrossrefPubMedGoogle Scholar
  • 54 Singer DE, Chang Y, Fang MC , et al. Should patient characteristics influence target anticoagulation intensity for stroke prevention in nonvalvular atrial fibrillation?: the ATRIA study. Circ Cardiovasc Qual Outcomes 2009; 2 (4) 297-304
    CrossrefPubMedGoogle Scholar
  • 55 Eriksson BI, Dahl OE, Büller HR , et al; BISTRO II Study Group. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 2005; 3 (1) 103-111
    CrossrefPubMedGoogle Scholar
  • 56 Reilly PA, Lehr T, Haertter S , et al; RE-LY Investigators. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol 2014; 63 (4) 321-328
    CrossrefPubMedGoogle Scholar
  • 57 US Food and Drug Administration. Briefing Information for the September 8, 2011 Meeting of the Cardiovascular and Renal Drugs Advisory Committee. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM270796.pdf . Accessed November 12, 2014
    PubMedGoogle Scholar
  • 58 US Food and Drug Administration. FDA Briefing Information for the October 30, 2014 Meeting of the Cardiovascular and Renal Drugs Advisory Committee. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM420704.pdf . Accessed November 12, 2014
    PubMedGoogle Scholar
  • 59 US Food and Drug Administration. Daiichi Sankyo Briefing Information for the October 30, 2014 Meeting of the Cardiovascular and Renal Drugs Advisory Committee. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM420705.pdf . Accessed: November 12, 2014
    PubMedGoogle Scholar
  • 60 Chin PK, Wright DF, Patterson DM, Doogue MP, Begg EJ. A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time. Br J Clin Pharmacol 2014; 78 (3) 599-609
    CrossrefPubMedGoogle Scholar
  • 61 Ebner T, Wagner K, Wienen W. Dabigatran acylglucuronide, the major human metabolite of dabigatran: in vitro formation, stability, and pharmacological activity. Drug Metab Dispos 2010; 38 (9) 1567-1575
    CrossrefPubMedGoogle Scholar
  • 62 Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008; 36 (2) 386-399
    CrossrefPubMedGoogle Scholar
  • 63 Mueck W, Stampfuss J, Kubitza D, Becka M. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet 2014; 53 (1) 1-16
    CrossrefPubMedGoogle Scholar
  • 64 Raghavan N, Frost CE, Yu Z , et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 2009; 37 (1) 74-81
    CrossrefPubMedGoogle Scholar
  • 65 Weinz C, Schwarz T, Kubitza D, Mueck W, Lang D. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug Metab Dispos 2009; 37 (5) 1056-1064
    CrossrefPubMedGoogle Scholar
  • 66 Stangier J, Stähle H, Rathgen K, Roth W, Shakeri-Nejad K. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment. J Clin Pharmacol 2008; 48 (12) 1411-1419
    CrossrefPubMedGoogle Scholar
  • 67 Stangier J, Stähle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 2008; 47 (1) 47-59
    CrossrefPubMedGoogle Scholar
  • 68 Härtter S, Koenen-Bergmann M, Sharma A , et al. Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin. Br J Clin Pharmacol 2012; 74 (3) 490-500
    CrossrefPubMedGoogle Scholar
  • 69 Zhang L, Zhang Y, Huang SM. Scientific and regulatory perspectives on metabolizing enzyme-transporter interplay and its role in drug interactions: challenges in predicting drug interactions. Mol Pharm 2009; 6 (6) 1766-1774
    CrossrefPubMedGoogle Scholar
  • 70 Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care 2009; 15 (6) e22-e33
    PubMedGoogle Scholar
  • 71 Laliberté F, Bookhart BK, Nelson WW , et al. Impact of once-daily versus twice-daily dosing frequency on adherence to chronic medications among patients with venous thromboembolism. Patient 2013; 6 (3) 213-224
    CrossrefPubMedGoogle Scholar
  • 72 Laliberté F, Nelson WW, Lefebvre P, Schein JR, Rondeau-Leclaire J, Duh MS. Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients. Adv Ther 2012; 29 (8) 675-690
    CrossrefPubMedGoogle Scholar
  • 73 Assawasuwannakit P, Rhiannon B, Duffull SB. Development of a criterion to quantify forgiveness. Available at: http://www.paganz.org/abstracts/development-of-a-criterion-to-quantify-forgiveness/ . Accessed November 15, 2014
    PubMedGoogle Scholar
  • 74 US Food and Drug Administration. Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products — general considerations. Available at: http://www.fda.gov/downloads/Drugs/Guidances/ucm070124.pdf . Accessed April 2, 2014
    PubMedGoogle Scholar
  • 75 Polasek TM, Lin FP, Miners JO, Doogue MP. Perpetrators of pharmacokinetic drug-drug interactions arising from altered cytochrome P450 activity: a criteria-based assessment. Br J Clin Pharmacol 2011; 71 (5) 727-736
    CrossrefPubMedGoogle Scholar
  • 76 Kubitza D, Becka M, Roth A, Mueck W. The influence of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban—an oral, direct Factor Xa inhibitor. J Clin Pharmacol 2013; 53 (3) 249-255
    CrossrefPubMedGoogle Scholar
  • 77 US Food and Drug Administration. Eliquis: Clinical Pharmacology & Biopharmaceutical Review(s). Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202155Orig1s000ClinPharmR.pdf . Accessed November 18, 2014
    PubMedGoogle Scholar
  • 78 Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J Clin Pharmacol 2007; 47 (2) 218-226
    CrossrefPubMedGoogle Scholar
  • 79 Upreti VV, Wang J, Barrett YC , et al. Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. Br J Clin Pharmacol 2013; 76 (6) 908-916
    CrossrefPubMedGoogle Scholar
  • 80 Stangier J, Rathgen K, Stähle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010; 49 (4) 259-268
    CrossrefPubMedGoogle Scholar
  • 81 Kubitza D, Becka M, Mueck W , et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol 2010; 70 (5) 703-712
    CrossrefPubMedGoogle Scholar
  • 82 Kubitza D, Roth A, Becka M , et al. Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol 2013; 76 (1) 89-98
    CrossrefPubMedGoogle Scholar
  • 83 Mueck W, Kubitza D, Becka M. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol 2013; 76 (3) 455-466
    CrossrefPubMedGoogle Scholar
  • 84 Frost CE, Byon W, Song Y , et al. Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. Br J Clin Pharmacol 2014 (e-pub ahead of print). Available at: http://onlinelibrary.wiley.com/doi/10.1111/bcp.12541/abstract . Accessed November 17, 2014
    PubMedGoogle Scholar
  • 85 Delavenne X, Ollier E, Basset T , et al. A semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycin. Br J Clin Pharmacol 2013; 76 (1) 107-113
    CrossrefPubMedGoogle Scholar
  • 86 Brunet A, Hermabessiere S, Benain X. Pharmacokinetic and pharmacodynamic interaction of dronedarone and dabigatran in healthy subjects. Eur Heart J 2011; 32 (Suppl. 01) 618
    CrossrefPubMedGoogle Scholar
  • 87 Mendell J, Zahir H, Matsushima N , et al. Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs 2013; 13 (5) 331-342
    CrossrefPubMedGoogle Scholar
  • 88 Huisman MV, Lip GY, Diener HC, Brueckmann M, van Ryn J, Clemens A. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost 2012; 107 (5) 838-847
    Article in Thieme ConnectPubMedGoogle Scholar
  • 89 Härtter S, Sennewald R, Nehmiz G, Reilly P. Oral bioavailability of dabigatran etexilate (Pradaxa(®) ) after co-medication with verapamil in healthy subjects. Br J Clin Pharmacol 2013; 75 (4) 1053-1062
    CrossrefPubMedGoogle Scholar
  • 90 Härtter S, Sennewald R, Schepers C, Baumann S, Fritsch H, Friedman J. Pharmacokinetic and pharmacodynamic effects of comedication of clopidogrel and dabigatran etexilate in healthy male volunteers. Eur J Clin Pharmacol 2013; 69 (3) 327-339
    CrossrefPubMedGoogle Scholar
  • 91 Kubitza D, Becka M, Mück W, Schwers S. Effect of co-administration of rivaroxaban and clopidogrel on bleeding time, pharmacodynamics and pharmacokinetics: a phase I study. Pharmaceuticals (Basel) 2012; 5 (3) 279-296
    CrossrefPubMedGoogle Scholar
  • 92 Stangier J, Rathgen K, Stähle H, Reseski K, Körnicke T, Roth W. Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics. Am J Cardiovasc Drugs 2009; 9 (1) 59-68
    CrossrefPubMedGoogle Scholar
  • 93 Kubitza D, Becka M, Roth A, Mueck W. Absence of clinically relevant interactions between rivaroxaban—an oral, direct Factor Xa inhibitor—and digoxin or atorvastatin in healthy subjects. J Int Med Res 2012; 40 (5) 1688-1707
    CrossrefPubMedGoogle Scholar
  • 94 Kubitza D, Becka M, Mueck W, Zuehlsdorf M. Rivaroxaban (BAY 59-7939)—an oral, direct Factor Xa inhibitor—has no clinically relevant interaction with naproxen. Br J Clin Pharmacol 2007; 63 (4) 469-476
    CrossrefPubMedGoogle Scholar
  • 95 Frost C, Shenker A, Gandhi MD , et al. Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban. Br J Clin Pharmacol 2014; 78 (4) 877-885
    CrossrefPubMedGoogle Scholar
  • 96 Mendell J, Chen S, He L, Desai M, Parasrampuria D. The effect of rifampin on the pharmacokinetics (PK) and pharmacodynamics (PD) of edoxaban in healthy subjects. J Thromb Haemost 2014; 12 (Suppl S1): 17
    PubMedGoogle Scholar
  • 97 Begg EJ, Chin PK. A unified pharmacokinetic approach to individualized drug dosing. Br J Clin Pharmacol 2012; 73 (3) 335-339
    CrossrefPubMedGoogle Scholar
  • 98 Anderson BJ, Holford NH. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet 2009; 24 (1) 25-36
    CrossrefPubMedGoogle Scholar
  • 99 Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16 (1) 31-41
    Google Scholar
  • 100 Levey AS, Stevens LA, Schmid CH , et al; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150 (9) 604-612
    CrossrefPubMedGoogle Scholar
  • 101 Lippi G, Favaloro EJ, Mattiuzzi C. Combined administration of antibiotics and direct oral anticoagulants: a renewed indication for laboratory monitoring?. Semin Thromb Hemost 2014; 40 (7) 756-765
    Article in Thieme ConnectPubMedGoogle Scholar
  • 102 Paré G, Eriksson N, Lehr T , et al. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation 2013; 127 (13) 1404-1412
    CrossrefPubMedGoogle Scholar
  • 103 Howey OK, Chin PK. Usage of renal function equations to guide prescribing in general medicine. N Z Med J 2013; 126 (1383) 97-99
    PubMedGoogle Scholar
  • 104 Chin PK, Florkowski CM, Begg EJ. The performances of the Cockcroft-Gault, modification of diet in renal disease study and chronic kidney disease epidemiology collaboration equations in predicting gentamicin clearance. Ann Clin Biochem 2013; 50 (Pt 6) 546-557
    CrossrefPubMedGoogle Scholar
  • 105 Chin PK, Wright DF, Zhang M , et al. Correlation between trough plasma dabigatran concentrations and estimates of glomerular filtration rate based on creatinine and cystatin C. Drugs R D 2014; 14 (2) 113-123
    CrossrefPubMedGoogle Scholar
  • 106 Moore KT, Vaidyanathan S, Natarajan J, Ariyawansa J, Haskell L, Turner KC. An open-label study to estimate the effect of steady-state erythromycin on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban in subjects with renal impairment and normal renal function. J Clin Pharmacol 2014; 54 (12) 1407-1420
    CrossrefPubMedGoogle Scholar
  • 107 Chagnac A, Weinstein T, Korzets A, Ramadan E, Hirsch J, Gafter U. Glomerular hemodynamics in severe obesity. Am J Physiol Renal Physiol 2000; 278 (5) F817-F822
    CrossrefPubMedGoogle Scholar
  • 108 Pai MP. Estimating the glomerular filtration rate in obese adult patients for drug dosing. Adv Chronic Kidney Dis 2010; 17 (5) e53-e62
    CrossrefPubMedGoogle Scholar
  • 109 Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis 2011; 31 (3) 326-343
    CrossrefPubMedGoogle Scholar
  • 110 Hirsh J, Dalen JE, Anderson DR , et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1998; 114 (5, Suppl): 445S-469S
    CrossrefPubMedGoogle Scholar
  • 111 Heidbuchel H, Verhamme P, Alings M , et al. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J 2013; 34 (27) 2094-2106
    CrossrefPubMedGoogle Scholar
  • 112 Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis 2012; 23 (2) 138-143
    CrossrefPubMedGoogle Scholar
  • 113 Tripodi A. The laboratory and the new oral anticoagulants. Clin Chem 2013; 59 (2) 353-362
    CrossrefPubMedGoogle Scholar
  • 114 Harenberg J, Kraemer R. Measurement of the new anticoagulants. Thromb Res 2012; 129 (Suppl. 01) S106-S113
    CrossrefPubMedGoogle Scholar
  • 115 Cuker A, Siegal DM, Crowther MA, Garcia DA. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol 2014; 64 (11) 1128-1139
    CrossrefPubMedGoogle Scholar
  • 116 Harenberg J, Kraemer S, Du S , et al. Determination of direct oral anticoagulants from human serum samples. Semin Thromb Hemost 2014; 40 (1) 129-134
    Article in Thieme ConnectPubMedGoogle Scholar
  • 117 Samama MM, Martinoli JL, LeFlem L , et al. Assessment of laboratory assays to measure rivaroxaban—an oral, direct factor Xa inhibitor. Thromb Haemost 2010; 103 (4) 815-825
    Article in Thieme ConnectPubMedGoogle Scholar
  • 118 Harenberg J, Du S, Weiss C, Krämer R, Hoppensteadt D, Walenga J ; working party: methods to determine apixaban of the Subcommittee on Control of Anticoagulation of the International Society of Thrombosis and Haemostasis. Report of the Subcommittee on Control of Anticoagulation on the determination of the anticoagulant effects of apixaban: communication from the SSC of the ISTH. J Thromb Haemost 2014; 12 (5) 801-804
    CrossrefPubMedGoogle Scholar
  • 119 Harenberg J, Marx S, Weiss C, Krämer R, Samama M, Schulman S ; Subcommittee on Control of Anticoagulation of the ISTH. Report of the Subcommittee of Control of Anticoagulation on the determination of the anticoagulant effects of rivaroxaban. J Thromb Haemost 2012; 10 (7) 1433-1436
    CrossrefPubMedGoogle Scholar
  • 120 Lippi G, Favaloro EJ. Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants (DOACs): is there consensus?. Clin Chem Lab Med 2015; 53 (2) 185-197
    PubMedGoogle Scholar